A round-up of IP-related quotes, observations and opinions from the recent past ...
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
@IAM_magazine Addressing the patent situation around Gilead's remdesivir, a top Chinese patent office official signaled the need… https://t.co/RdRFPUGE1v Read more
@IAM_magazine RT @ktMINEglobal: The countdown revealing the companies in this year's @IAM_magazine / ktMINE US Patent 100 continues by naming those in pl… Read more
@IAM_magazine It's part 2 of the IAM/@ktMINE US Patent 100 countdown of the world's largest US patent portfolios today - and we'r… https://t.co/nFZA7vYOOc Read more
@IAM_magazine Despite a drop-off in deal numbers, 2019 was a great year for biopharma IP owners: https://t.co/DA83FMQREB https://t.co/UEzyNeRuyH Read more